ASTRO: SABR Offers Long-Term Benefits Comparable to Surgery for Non-Small Cell Lung Cancer Comparable overall survival seen at seven and 10 years, lung cancer-specific survival, and recurrence-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback